![]() |
|
|
Vol. 26, Issue 6, 536-539, June 1998
Quebec Heart Institute, Laval Hospital, and Faculty of Pharmacy,
Laval University
Classic antihistamines, namely diphenhydramine, chlorpheniramine,
clemastine, perphenazine, hydroxyzine, and tripelennamine, share
structural features with substrates and inhibitors of the polymorphic
cytochrome P450 (CYP) isozyme CYP2D6. Therefore, the current study was
undertaken to characterize the in vitro inhibition of
CYP2D6 by these commonly used, histamine H1
receptor antagonists. Microsomal incubations were performed using
bufuralol as a specific CYP2D6 substrate and microsomes derived from
human cells transfected with CYP2D6 cDNA. Reaction velocities were
assessed in the absence and presence of antihistamines (20 µM) at 11 substrate concentrations (1, 2.5, 5, 7.5, 10, 15, 20, 25, 50, 75, and
100 µM), as well as at three nonsaturating substrate concentrations
(2.5, 5, and 20 µM) and three inhibitor concentrations (5, 20, and 50 µM). In the presence of all antihistamines, the
Vmax and KM
of bufuralol 1'-hydroxylation were significantly altered, compared with
the uninhibited reaction (p < 0.05).
Lineweaver-Burke plots suggested competitive inhibition of the reaction
by diphenhydramine and mixed inhibition by all other antihistamines
tested. Diphenhydramine and chlorpheniramine, with estimated
Ki values of ~11 µM, were the weakest
inhibitors of CYP2D6 in vitro. Whereas tripelennamine, promethazine, and hydroxyzine were similar in their inhibitory capacities (Ki ~ 4-6 µM), clemastine
appeared to be significantly more potent, with a
Ki of ~2 µM. These data demonstrate
that classic histamine H1 receptor antagonists,
available in over-the-counter preparations, inhibit CYP2D6 in
vitro. Furthermore, the CYP2D6-inhibitory concentrations of these
antihistamines are in the range of their expected hepatic blood
concentrations, suggesting that, under specific circumstances,
clinically relevant interactions between classic antihistamines and
CYP2D6 substrates might occur.
This article has been cited by other articles:
![]() |
S. Frick, M. Roos, and K. Fattinger How much is too much? Oligosymptomatic presentation after 11.5 g of diphenhydramine Human and Experimental Toxicology, February 1, 2007; 26(2): 131 - 133. [Abstract] [PDF] |
||||
![]() |
T. Akutsu, K. Kobayashi, K. Sakurada, H. Ikegaya, T. Furihata, and K. Chiba Identification of Human Cytochrome P450 Isozymes Involved in Diphenhydramine N-Demethylation Drug Metab. Dispos., January 1, 2007; 35(1): 72 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Armstrong and K. L. Cozza Antihistamines Psychosomatics, October 1, 2003; 44(5): 430 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Khalifa, B. Drolet, P. Daleau, C. Lefez, M. Gilbert, S. Plante, G. E. O'Hara, O. Gleeton, B. A. Hamelin, and J. Turgeon Block of Potassium Currents in Guinea Pig Ventricular Myocytes and Lengthening of Cardiac Repolarization in Man by the Histamine H1 Receptor Antagonist Diphenhydramine J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 858 - 865. [Abstract] [Full Text] |
||||